Articles related to Oncology, Surgical

A 51-year-old woman’s case of Meigs’ syndrome underscores the importance of distinguishing this benign condition from ovarian cancer, emphasizing the resolution of symptoms following the excision of the ovarian fibroma.

The FDA has withdrawn approval for infigratinib in advanced cholangiocarcinoma following Helsinn Healthcare SA’s request, citing recruitment difficulties for a confirmatory trial.

Secondary malignancies like indolent CD4+ CAR T-cell lymphoma can emerge after CAR T-cell therapy. This case highlights the importance of recognizing and thoroughly investigating these rare complications.

The occurrence of second tumors, such as T-cell lymphomas, post-CAR T-cell therapy is rare. The study identifies Epstein-Barr virus and mutant clonal hematopoiesis as potential factors but finds no evidence of oncogenic retroviral integration, providing valuable insights for clinical practice.

In a phase 2 study of patients with locally advanced mismatch repair–deficient colon cancer, treatment with neoadjuvant nivolumab plus ipilimumab resulted in a 98% pathological response rate and a 68% pathological complete response rate, with no recurrence of disease observed over a median follow-up of 26 months.

In a phase 3 trial, osimertinib significantly improved median progression-free survival to 39.1 months in patients with unresectable stage III EGFR-mutated NSCLC following chemoradiotherapy, compared to 5.6 months with placebo.